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Abstract
Background: Proteolytic processing of the Lassa virus envelope glycoprotein precursor GP-C by the host proprotein
convertase site 1 protease (S1P) is a prerequisite for the incorporation of the subunits GP-1 and GP-2 into viral particles and,
hence, essential for infectivity and virus spread. Therefore, we tested in this study the concept of using S1P as a target to
block efficient virus replication.
Methodology/Principal Finding: We demonstrate that stable cell lines inducibly expressing S1P-adapted a1-antitrypsin
variants inhibit the proteolytic maturation of GP-C. Introduction of the S1P recognition motifs RRIL and RRLL into the
reactive center loop of a1-antitrypsin resulted in abrogation of GP-C processing by endogenous S1P to a similar level
observed in S1P-deficient cells. Moreover, S1P-specific a1-antitrypsins significantly inhibited replication and spread of a
replication-competent recombinant vesicular stomatitis virus expressing the Lassa virus glycoprotein GP as well as authentic
Lassa virus. Inhibition of viral replication correlated with the ability of the different a1-antitrypsin variants to inhibit the
processing of the Lassa virus glycoprotein precursor.
Conclusions/Significance: Our data suggest that glycoprotein cleavage by S1P is a promising target for the development of
novel anti-arenaviral strategies.
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Introduction
Lassa virus (LASV) belongs to the family Arenaviridae, which are
enveloped, single-stranded RNA viruses distributed worldwide.
Based on their antigenic relationships and geographic distribution,
arenaviruses are divided into two major groups. The Old World
group includes the prototype of this family, lymphocytic
choriomeningitis virus (LCMV), and LASV, which is endemic in
West African countries and causes every year thousands of human
infections with hemorrhagic fever as a severe clinical manifestation
[1]. The New World group includes among others Machupo,
Junin, Guanarito and Sabia viruses which can cause viral
hemorrhagic fever (VHF). With the exception of the New World
virus Tacaribe, which was isolated from Artibeus bats, arenaviruses
are rodent-borne viruses [2].
Over the past few years great efforts have been made to find
potential therapeutic and vaccination approaches in the arenavirus
field (reviewed in [3,4,5]). Until now there is no specific and
effective treatment available to combat hemorrhagic fevers caused
by arenaviruses. Administration of convalescent plasma has been
reported to reduce the mortality rates of patients with Argentine
hemorrhagic fever, however, 10% of immune-plasma recipients
developed a late neurological syndrome of unknown origin [6].
The only existing drug used to treat Lassa fever and certain South
American hemorrhagic fevers is the broad-spectrum antiviral
agent ribavirin, a ribonucleoside analogue, which has shown to be
partially effective if given early in the course of illness [7,8,9,10].
Even though the drug is relatively inexpensive for patients in high-
developed countries, it is still unaffordable for many of those living
in West Africa and South America. Moreover, several adverse
effects have been associated with ribavirin therapy in patient
studies and animal models [11,12,13,14,15]. The lack of effective
disease control measures as well as the discovery of new fatal
arenavirus species that pose a risk of epidemic potential [16,17],
emphasize the need for novel therapeutic interventions.
Lassa virions are pleomorphic lipid-enveloped particles that
contain two single-stranded RNA segments, designated L (large)
and S (small), encoding four viral proteins in a unique ambisense
coding strategy. The L segment encodes the viral RNA-dependent
RNA polymerase (L) and the small zinc finger matrix protein (Z)
[18]; the S segment encodes the virus nucleoprotein (NP) and the
virus surface glycoprotein precursor (preGP-C) [19]. preGP-C is
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[20]. Post-translational maturation cleavage of GP-C by the
proprotein convertase site 1 protease (S1P, [21]), also known as
subtilisin kexin isozyme-1 (SKI-1, [22]), leads then to the
generation of the distal receptor-binding subunit GP-1 and the
transmembrane-spanning fusion competent subunit GP-2 [23].
Together with the signal peptide these subunits form the tripartite
glycoprotein spike complex on the viral surface [24,25].
The glycoproteins of the Old World arenaviruses LASV and
LCMV were the first viral glycoproteins that were shown to be
proteolytically processed by S1P [23,26], which normally plays
important physiological regulatory roles in cholesterol metabolism,
ER stress response, cartilage development and other cellular
processes [21,27,28,29,30,31]. Using systematic mutational anal-
ysis of the LCMV GP cleavage site, the consensus motif R-(R/K/
H)-L-(A/L/S/T/F) was determined, which is conserved in the
glycoprotein sequences of the Old World viruses LASV, Mopeia
and Mobala, as well as the New World virus Pichinde, suggesting
that all arenavirus glycoproteins are cleaved by S1P [26,32].
Indeed, more recently Rojek et al. reported that glycoproteins
from the New World hemorrhagic fever viruses Junin, Machupo
and Guanarito are also processed by S1P, although Guanarito
possesses a protease recognition motif that differs from known
arenavirus GP consensus cleavage sequences, indicating a broader
substrate specificity of S1P than previously anticipated [33].
Proteolytic activation of LASV GP-C by S1P is not necessary
for transport of GP-C to the cell surface, where budding of
arenaviruses occurs, but is essential for incorporation of the
cleaved subunits into virions, and thus, for the formation of
infectious viral particles. In the absence of GP-C cleavage,
enveloped non-infectious LASV-like particles are released con-
taining L, NP, Z protein and viral RNA but are devoid of viral
glycoproteins [23]. Similar results were described for LCMV and
New World hemorrhagic fever viruses [33,34].
In addition to its important role in the arenaviral life cycle, S1P
is critical for the infectivity of Crimean-Congo hemorrhagic fever
virus (CCHFV), a member of the Bunyaviridae family, through
processing of the glycoprotein Gn [35,36]. These findings make
the inhibition of S1P particularly interesting for the development
of a novel antiviral therapeutic that will target pathogenic viruses
known to be processed by S1P.
A successful approach to inhibit proprotein convertases involves
genetically engineered antitrypsins, which are derived from a1-
antitrypsin (a1-AT). a1-AT is a serine protease inhibitor (serpin)
with a characteristic exposed reactive center loop (RCL), which
mediates binding to the active site of its target protease. The
exploration for the potential use of modified antitrypsins with an
altered inhibitory spectrum has been guided by the discovery of a
natural variant of a1-AT, known as Pittsburgh (a1-AT-PIT), found
in a patient who had a severe bleeding disorder caused by
mutation of the P1 reactive center residue of antitrypsin from
methionine to arginine [37]. This substitution changed its
specificity from elastase to thrombin and other coagulation
proteases. Due to the introduction of a second mutation from
alanine to arginine at P4 of the RCL, the engineered a1-
antitrypsin variant Portland (a1-AT-PDX) showed high affinity for
furin [38]. a1-AT-PDX efficiently inhibited the formation of
infectious HIV, measles virus, and human cytomegalovirus
progeny by blocking furin-dependent processing of glycoproteins
gp160, F0 and gB, respectively [38,39,40,41]. Pullikotil and co-
workers used this approach for the generation of highly selective
a1-antitrypsin variants specific for S1P by introducing various S1P
recognition motifs into the RCL of a1-antitrypsin [42]. The
adaptation of a1-antitrypsin towards S1P efficiently inhibited the
processing of the S1P substrates SREBP-2 (sterol regulatory
element binding protein), ATF6 (activating transcription factor 6)
as well as CCHFV glycoprotein [42]. However, the effect of these
inhibitors on CCHFV infection was not analyzed in that study. To
block cleavage of the LASV glycoprotein, we generated here
recombinant a1-antitrypsin variants mimicking the S1P recogni-
tion motifs RRIL, RRVL and RRYL that exhibited the greatest
inhibitory potential based on immunoblot quantification. In
addition, we used an a1-AT construct that contains the LASV
GP cleavage motif RRLL in its RCL. Using a doxycycline
regulated expression system we demonstrate that S1P-adapted a1-
antitrypsin variants efficiently block proteolytic maturation of the
glycoprotein precursor GP-C, whereas a furin-specific a1-AT had
no effect on GP-C processing. Virus replication of both a
replication-competent recombinant vesicular stomatitis virus
expressing the LASV glycoprotein GP-C (VSVDG/LASVGP)
and authentic LASV was significantly inhibited in the presence of
S1P-specific a1-antitrypsins. The degree of inhibition of viral
replication correlated with the ability of the different a1-antitrypsin
variants to inhibit the processing of LASV GP-C.
Since glycoprotein processing by the endoprotease S1P is not
only critical for virus infectivity of LASV [23], and other
arenaviruses causing hemorrhagic fever [33], but also for members
of the Bunyaviridae family [36], further optimization based on our
findings could lead to a potent and specific S1P inhibitor with the
potential treatment of certain VHFs.
Materials and Methods
Molecular cloning and expression
cDNA of the open reading frame of rat a1-antitrypsin (Gene
Bank Accession Number NM_022519) (a kind gift from Dr. G.
Thomas, Vollum Institute, Oregon Health & Science University,
Portland, USA) was inserted into pSG5 and used as a template to
generate S1P-specific a1-antitrypsin variants by recombinant
polymerase chain reaction (PCR) using overlapping oligonucleo-
tides [43]. The sequences of the oligonucleotides used are listed in
Table S1. The resulting full-length PCR products were digested
Author Summary
The virus family Arenaviridae includes several hemorrhagic
fever causing agents such as Lassa, Guanarito, Junin,
Machupo, and Sabia virus that pose a major public health
concern to the human population in West African and
South American countries. Current treatment options to
control fatal outcome of disease are limited to the
ribonucleoside analogue ribavirin, although its use has
some significant limitations. The lack of effective treatment
alternatives emphasizes the need for novel antiviral
therapeutics to counteract these life-threatening infec-
tions. Maturation cleavage of the viral envelope glycopro-
tein by the host cell proprotein convertase site 1 protease
(S1P) is critical for infectious virion production of several
pathogenic arenaviruses. This finding makes this protease
an attractive target for the development of novel anti-
arenaviral therapeutics. We demonstrate here that highly
selective S1P-adapted a1-antitrypsins have the potential to
efficiently inhibit glycoprotein processing, which resulted
in reduced Lassa virus replication. Our findings suggest
that S1P should be considered as an antiviral target and
that further optimization of modified a1-antitrypsins could
lead to potent and specific S1P inhibitors with the
potential for treatment of certain viral hemorrhagic fevers.
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controlled inducible mammalian expression vector pTRE2hyg
(Clontech). The accuracy of all constructs was confirmed by DNA
sequencing.
To generate stably expressing cell lines, Chinese hamster ovary
(CHO)-K1 Tet-On cells (Clontech) were transfected with
pTRE2hyg containing the a1-antitrypsin constructs using Lipo-
fectamine 2000 (Invitrogen) according to manufacturer’s instruc-
tions. Cells were then cultured for 2 weeks under selective pressure
in the presence of 500 mg/ml Hygromycin B, the selection agent
for the a1-antitrypsin expressing plasmid, and 500 mg/ml G418,
the selection agent for the rtTA (reverse Tet-controlled transacti-
vator) cassette. The selective media were replaced every 3 days.
Well-separated antibiotic-resistant cell clones were individually
isolated with cloning cylinders (Sigma). Therefore, a small volume
of Trypsin-EDTA (Sigma) was added and the culture dish was
incubated briefly at 37uC until cells detach. Cells were then
collected from inside the cylinder and transferred to individual
wells of a 24-well plate for further growth in selective medium.
When grown to confluence, cells were transferred to larger flasks.
Protein expression was induced with 1 mg/ml doxycycline
(Clontech) and analyzed by Western Blot and immunofluores-
cence. Stable cell lines showing similar expression levels of the
various a1-antitrypsins were chosen for further experiments.
Cell cultures
Vero E6 cells (green monkey kidney) were cultured in
Dulbecco’s modified Eagle medium (DMEM, Gibco) and CHO-
K1 Tet-On cells in DMEM/F12 (Gibco), both media containing
penicillin (100 U/ml), streptomycin (100 mg/ml), and L-glutamine
(2 mmol/l) (all from Invitrogen) as well as 10% fetal bovine serum
(PAN Biotech). S1P-deficient SRD-12B cells (a generous gift from
Dr. J. L. Goldstein, Department of Molecular Genetics, University
of Texas Southwestern Medical Center, Dallas, USA) were
maintained as CHO cells but supplemented with 5 mg/ml of
cholesterol (Sigma), 1 mM sodium mevalonate (Sigma), and
20 mM sodium oleate (Sigma) [44].
Viruses and infectious work
The vesicular stomatitis virus reverse genetics system (VSV,
Indiana serotype) was kindly provided by Dr. J.K. Rose
(Department of Pathology, Yale University School of Medicine,
New Haven, USA) and was described in detail earlier [45,46,47].
Recombinant VSV expressing the glycoprotein GP-C of Lassa
virus (LASV, strain Josiah) designated as VSVDG/LASVGP and
wild-type VSV (VSVwt) were propagated in Vero E6 cells as
described previously [48]. Influenza virus A/FPV/Rostock/34
(H7N1), designated as fowl plague virus (FPV), was propagated in
embryonated hen eggs and stored at 280uC until further use.
Virus titration of FPV was described previously [49]. All
experiments with infectious FPV were done under biological
safety level 3 conditions. VSVDG/LASVGP titration was
performed using a microplate format plaque assay with subsequent
immunostaining as described before [50]. In brief, virus dilutions
were incubated on Vero E6 cells with an overlay of 3%
carboxymethylcellulose (CMC) during plaque formation. Infected
cells were visualized after cell fixation with paraformaldehyde
(PFA, 4%) and permeabilization with 0.3% Triton-X 100 using a
specific LASV GP-C/GP-2 antibody followed by incubation with
horseradish peroxidase-labeled secondary anti-rabbit antibody
(DAKO). Finally, cells were stained with True Blue Peroxidase
substrate (KPL).
For virus spread experiments, CHO cell lines were seeded into
96-well plates in the presence or absence of doxycycline. 24 h after
induction, cells were infected with VSVDG/LASVGP or FPV and
were grown without solid overlay. Cells were fixed at different time
points post-infection and immunostaining was performed as
described above using rabbit sera against VSV (kindly provided
by Dr. G. Herrler, Institut fu ¨r Virologie, Zentrum fu ¨r Infektions-
medizin, Stiftung Tiera ¨rztliche Hochschule Hannover, Germany),
for the detection of VSVDG/LASVGP infected cells, and against
FPV, for cells infected with FPV, respectively.
Virus titration of LASV (strain Josiah, Gene Bank Accession
Number NC_004297 and NC_004296) was performed by defining
the 50% tissue culture infectious dose (TCID50). For this, Vero
cells were grown in 96-well plates to 30 to 40% confluence. Cells
were inoculated with 10-fold serial dilutions of supernatants from
LASV-infected CHO cell lines grown in the presence or absence
of doxycycline. The assays were evaluated at 7 to 9 days post-
infection. TCID50 values were calculated using the Spearman-
Karber method [51]. All experiments involving LASV-infected
samples were performed under biological safety level 4 conditions
at the Philipps-University Marburg.
Purification of viral particles from cellular supernatant
At 24 h post-infection, cell culture supernatants from infected
cells were cleared from cell debris and pelleted in an SW-60 rotor
through a 20% sucrose cushion at 52000 rpm at 4uC for 2 h. The
pellet was then resuspended in PBS buffer and mixed with SDS-
PAGE sample buffer. To control the intracellular expression level,
cell lysates were collected simultaneously. Samples were analyzed
by SDS-PAGE and Western blotting using protein-specific
antibodies as indicated.
Acrylamide gel electrophoresis and immunoblotting
Proteins were separated by SDS-PAGE using 10% polyacryl-
amide gels. Immunoblotting was performed as described previ-
ously [52]. Antiserum against Lassa virus GP-C/GP-2 was also
described previously [32]. Polyclonal rabbit anti-ß-tubulin anti-
body was purchased from Abcam (UK), and monoclonal mouse
anti-Flag antibody from Sigma-Aldrich. Secondary antibodies
labeled with Alexa680 or IRDye800 were from Molecular Probes
Invitrogen and Biomol, respectively, and were used for visualiza-
tion and quantification of detected proteins using the Odyssey
Infrared Imaging System (LI-COR Biosciences).
Immunofluorescence analysis
CHO cell lines were grown on coverslips and 24 h after
doxycycline-induction, cells were washed with PBS and fixed with
4% PFA in DMEM for 30 min. The fixative was removed, and
free aldehydes were quenched with 100 mM glycine in PBS.
Then, samples were washed with PBS and permeabilized for
10 min with PBS containing 0.1% Triton X-100. Cells were
incubated in blocking solution (2% bovine serum albumin, 0.2%
Tween 20, 5% glycerol, and 0.05% sodium azide in PBS) and
subsequently stained with a primary mouse-anti-flag antibody
(1:400) and a secondary anti-mouse antibody coupled to
rhodamine (1:200, Jackson Immunoresearch). Cell nuclei were
stained with DAPI (49,69-diamidino-2-phenylindole, Sigma).
Microscopic analysis was performed with a Zeiss ApoTome/
Axiovert 200 M microscope using a magnification of 1:40.
Results
Growth kinetics of VSVDG/LASVGP in CHO-K1 cells
Replication-competent recombinant vesicular stomatitis virus
(rVSV) expressing foreign envelope glycoproteins has been
demonstrated to be a suitable model system to study the role of
Effect of S1P Inhibition on LASV Replication
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the present study, we took advantage of a rVSV expressing the
LASV glycoprotein GP (designated VSVDG/LASVGP) [48]. In
this system biosynthesis and processing of GP was shown to be
authentic compared to LASV [48].
In an initial experiment we wanted to determine whether CHO-
K1 cells are susceptible to VSVDG/LASVGP infection. The
reason we chose CHO-K1 cells for our studies is the availability of
a site 1 protease-deficient CHO cell line (designated SRD-12B
cells), in which GP maturation is abolished and only GP-deficient
non-infectious LASV particles are released [23]. Thus, this cell
clone provides an ideal control for inhibition studies. Vero E6,
CHO-K1, and SRD-12B cells were infected with either VSVDG/
LASVGP or wild-type VSV (VSVwt) as a control. Aliquots of cell
culture supernatants were collected at different times after
infection and were analyzed by plaque assay. Growth kinetics
revealed that VSVDG/LASVGP grows to similar titers in CHO-
K1 cells compared to Vero E6 cells which have been used in
earlier studies (Fig. 1A) [48]. These data demonstrated that CHO-
K1 cells support efficient VSVDG/LASVGP replication, and thus
are useful tools for further investigations. As expected, VSVDG/
LASVGP lacks efficient replication in SRD-12B cells, whereas
virus growth of VSVwt remained unaffected in these cells (Fig. 1A).
The reason for the low but detectable virus titers in the
supernatant of VSVDG/LASVGP-infected SRD-12B cells is
currently not known but has been also observed for LASV ([23]
and present study), LCMV [34] and New Word arenaviruses [33].
Glycoprotein activation by a yet unknown protease though with
only very low efficiency might explain this phenomenon.
To mimic the conditions of short-term treatment, we decided to
use the inducible doxycycline-dependent Tet-On expression
system, which allows regulated expression of the protein of interest
[55]. To determine whether treatment of cells with doxycycline
interferes with viral replication, we cultivated VSVDG/LASVGP-
infected CHO-K1 Tet-On cells in the presence or absence of
doxycycline (1 mg/ml) for 24 h and 48 h, respectively. As shown in
Fig. 1B, CHO-K1 Tet-On cells treated with doxycycline produced
a virus titer comparable to cells that were cultivated in the absence
of doxycycline, indicating that these conditions used in our
experiments have no influence on efficient virus replication.
Generation of S1P-adapted a1-antitrypsin expressing cell
lines
Pullikotil and colleagues recently reported that various anti-
trypsins mimicking S1P recognition motifs are able to block
processing of the S1P substrates SREBP and ATF6, although to
different degrees [42]. In addition to the a1-AT variants shown to
be most effective in that study we have chosen the LASV GP-C
cleavage motif RRLL to investigate whether they also inhibit
LASV GP-C cleavage. Therefore, we generated various S1P-
specific a1-ATs, and as a specificity control, a furin-adapted a1-
AT, by recombinant PCR technology using the rat a1-AT-PIT as
a template (Fig. 2A). To facilitate their detection, we introduced a
flag epitope at the C-termini of the constructs. Stable cell lines
were generated and individual clones were isolated and screened
for a1-antitrypsin expression after doxycycline induction by
immunoblotting and immunofluorescence analysis. Cell lines that
showed similar expression levels of a1-antitrypsins were chosen for
further experiments (Fig. 2B and 2C).
Effect of S1P-specific a1-antitrypsins on LASV GP
processing
To test the inhibitory potential of S1P-specific a1-antitrypsins on
proteolytic processing of LASV GP, stably transfected CHO-K1
Tet-On cells, and non-transfected wild-type CHO-K1 Tet-On
cells as well as SRD-12B cells were infected with VSVDG/
LASVGP at an MOI of 0.2 in the presence or absence of
doxycycline. To allow only one replication cycle, cell lysates were
analyzed 10 h post-infection for detection of LASV GP cleavage
by Western blot analysis using a GP-specific antiserum that
recognizes both the precursor GP-C and the cleaved subunit GP-
2. In CHO-K1 Tet-On cells LASV GP was efficiently cleaved,
regardless of whether doxycycline was present or not. In contrast,
virtually no detectable cleavage of GP was observed in SRD-12B
cells that are deficient in S1P (Fig. 3A, lanes 1–4). Without
expression of the various antitrypsins efficient cleavage was
detected in these stably transfected cell lines, similar to the
processing of GP in wild-type CHO-K1 Tet-On cells (Fig. 3A,
lanes 1, 5, 7, 9, 11, and 13). In contrast, cells expressing the S1P-
adapted a1-antitrypsins inhibited proteolytic maturation of LASV
GP (Fig. 3A, lanes 6, 8, 10, and 12). Furthermore, our results show
Figure 1. Replication of VSVDG/LASVGP and VSVwt in CHO-K1 cells. A. CHO-K1, Vero E6, and SRD-12B cells were infected either with the
recombinant virus VSVDG/LASVGP or wild-type VSV (VSVwt) at an MOI of 0.02. Supernatants were collected at different times and titrated by plaque
assay. The growth curves shown are the mean result6standard deviation of three independent experiments. B. CHO-K1 Tet-On cells were infected
with VSVDG/LASVGP in the presence (+) or absence (2) of doxycycline (Dox, 1 mg/ml) at an MOI of 0.02. Supernatants were sampled 24 h and 48 h
post-infection and analyzed by plaque assay.
doi:10.1371/journal.pntd.0000446.g001
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GP-C processing, demonstrating the specificity of the generated
S1P-adapted a1-antitrypsins (Fig. 3A, lanes 13 and 14). Quanti-
fication of GP-2 cleavage revealed that the a1-AT variant RRIL
exhibited the greatest inhibitory effect on GP processing (.80%
inhibition) followed by a1-AT RRLL (.60% inhibition), which
possesses the amino acid cleavage motif of the LASV GP-C. Also
a1-AT variants RRVL and RRYL were found to be inhibitory,
although to a lesser extent (inhibition less than 50%) than the
variants RRIL and RRLL (Fig. 3B). Taken together, these data
clearly demonstrate that S1P-specific a1-antitrypsins efficiently
block the maturation cleavage of LASV GP, however, they differ
in regard to their inhibitory potential.
S1P-specific a1-antitrypsin prevents LASV GP
incorporation into virions
We have shown earlier that S1P-mediated cleavage of GP-C is
absolutely required for incorporation of the glycoprotein subunits
into the virion envelope and thus for production of infectious
LASV [23]. Therefore, we addressed the question of whether a
S1P-specific a1-AT has the potential to prevent GP incorporation
by blocking glycoprotein processing. To this end, a1-AT RRIL
cells were infected in the presence or absence of doxycycline with
either VSVDG/LASVGP or VSVwt as a control. At 24 h post-
infection, viral particles released into the cell culture supernatant
were purified over a 20% sucrose cushion and analyzed by means
of immunoblotting. In viral particles from supernatants of non-
induced a1-AT RRIL cells and CHO-K1 Tet-On control cells
cleaved GP-2 was readily observed, whereas in the particulate
material isolated from the supernatant of a1-AT RRIL expressing
cells no glycoprotein was detected (Fig. 4A). However, Western
Blot analysis for VSV proteins revealed the release of these viral
proteins into the supernatant of a1-AT RRIL expressing cells,
which is consistent with our earlier findings that, in the absence of
GP-C cleavage, enveloped non-infectious LASV-like particles
containing the matrix protein Z and the ribonucleoprotein (RNP)
complex, but devoid of viral glycoproteins, are still released [23].
The lower amount of VSV proteins observed in the cell lysate and
supernatant of a1-AT RRIL expressing cells reflect lower levels of
viral replication, which is due to less efficient virus spread (Fig. 4A).
In contrast to its ability to efficiently block incorporation of LASV
GP into virions, the presence of a1-AT RRIL had no effect on the
release of glycoprotein G containing wild-type VSV particles. The
amount of VSV proteins detected in the supernatant from a1-AT
RRIL expressing cells was similar to the amount of viral proteins
observed in supernatants of non-induced cells and CHO-K1 cells,
indicating efficient viral replication and cell-to-cell spread of
VSVwt despite the presence of a1-AT RRIL (Fig. 4B). Taken
together, these data demonstrate that S1P-specific a1-antitrypsins
have the potential to prevent LASV GP incorporation by
inhibiting glycoprotein cleavage, which is an essential prerequisite
for infectious progeny.
Virus spread is reduced in the presence of specific a1-
antitrypsins
Next, we wanted to know whether the observed inhibition of
LASV GP processing correlates with the ability of the different a1-
antitrypsin variants to inhibit virus spread. To investigate this, we
established a 96-well plate assay in which infected cells are
immunostained with True Blue substrate as described in Materials
and Methods. Virus spread can be monitored by the appearance
of characteristic comet-shaped foci, showing that the virus progeny
is carried over the cell monolayer, while prevention of virus spread
results in limited radial growth, due to infection of only
neighbouring cells. This assay allows rapid screening of potential
inhibitors [50]. To this end, doxycycline-induced and non-induced
CHO cell lines, as well as CHO-K1 Tet-On cells and SRD-12B
cells, were infected with VSVDG/LASVGP. At 24 h post-
infection, cells were fixed and immunostained. Under non-induced
conditions efficient virus spread was observed in all CHO-K1 Tet-
On a1-AT variant cell lines as well as in CHO-K1 Tet-On wild-
Figure 2. Generation of stably transfected a1-antitrypsin cell
lines. A. Schematic representation of constructed a1-antitrypsin
variants used for generation of stable cell lines. The amino acid
sequences of the different motifs introduced into the RCL by
recombinant PCR technology are shown in one-letter code. To facilitate
their detection, a flag epitope was introduced at the C-terminus as
indicated. B. Cellular expression of a1-antitrypsin variants. CHO-K1 Tet-
On a1-ATs cells were induced with doxycycline (Dox, 1 mg/ml) or left
untreated. At 24 h post-induction, cell lysates were analyzed by
immunoblot analysis using a mouse anti-flag antibody. b-tubulin
served as a loading control using a rabbit anti-ß-tubulin antibody. C.
Immunofluorescence analysis of a1-antitrypsin expression. CHO-K1 Tet-
On and a1-antitrypsin expressing cells were fixed with 4% PFA and
permeabilized using 0.1% Triton X-100. a1-antitrypsin variants were
visualized with a primary anti-flag mouse antibody and a secondary
anti-mouse antibody coupled to rhodamine. Cell nuclei were stained
with DAPI.
doi:10.1371/journal.pntd.0000446.g002
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significantly diminished in cells expressing a1-AT specific for S1P
(Fig. 5A, lower panel). These data indicate that S1P-adapted a1-
antitrypsins have the potential to specifically inhibit the processing
of LASV GP, which in turn is required for efficient virus spread. It
should be noted that the infectious foci observed in a1-AT RRIL
expressing cells were larger compared to SRD-12B cells in which
virtually no virus spread of VSVDG/LASVGP was observed,
resulting in only single infected cells (Fig. 5A). Although similar
inhibition values were observed by means of immunoblot
quantification (Fig. 3), a few remaining non-detectable cleavage
events may count for this limited cell-to-cell spread in a1-AT
RRIL expressing cells. Cells expressing the furin-adapted a1-AT
variant RVKR did not prevent virus spread. At first glance, we
rather observed an enhancement of infectivity compared to non-
induced cells, which might be due to an increase in the LASV
cellular receptor a-dystroglycan on the cell surface [56].
To further confirm the specificity of the a1-AT variants, we used
fowl plague virus (FPV), which contains a hemagglutinin with a
multibasic cleavage motif recognized by furin [57]. Thus, the
furin-adapted a1-AT should prevent virus spread of FPV, while
virus spread in the presence of S1P-specific a1-antitrypsins should
remain unaffected. Fig. 5B clearly demonstrates that the most
potent S1P-specific a1-AT variant RRIL had no effect on FPV
replication, and that virus spread was found to be similar to that
observed in wild type CHO-K1 Tet-On cells. In contrast, in cells
expressing the furin-adapted a1-AT variant RVKR virus spread of
FPV was drastically reduced, whereas FPV replication occurred
efficiently under doxycycline-free conditions in these cells. These
results demonstrate that the generated a1-AT variants exhibit high
specificity for the corresponding proteases, which are essential for
virus spread in cell culture.
Effect of a1-antitrypsin variants on recombinant viral
replication
To further elucidate the effect of the different a1-AT variants on
multicycle replication, viral titers were determined. To this end,
cells were infected with VSVDG/LASVGP at an MOI of 0.02 in
the presence or absence of doxycycline. Cell culture supernatants
were collected 24 h and 48 h post-infection and virus titers were
determined by plaque assay. As shown in Table 1, non-induced
S1P-specific a1-AT cell lines permitted unaffected growth of
Figure 3. Effect of S1P-adapted a1-antitrypsins on LASV GP-C cleavage. A. CHO-K1 Tet-On cells (lanes 1 and 2), S1P-deficient SRD-12B cells
(lanes 3 and 4) and CHO-K1 Tet-On cell lines stably transfected with plasmids encoding a1-antitrypsin variants (lanes 5–14) were infected with VSVDG/
LASVGP at an MOI of 0.2 in the presence (+) or absence (2) of doxycycline (Dox, 1 mg/ml) as indicated. At 10 h post-infection cell lysates were
analyzed by Western blot analysis using specific antibodies as described in the Materials & Methods. B. Efficiency of GP-C cleavage was quantified by
infrared fluorescent imaging using the Odyssey infrared imaging system. The amount of GP-2 was quantified compared to total amount of GP-C.
Detected GP-2 in induced cell lines was calculated in relation to the corresponding non-induced cells, which were adjusted to 100%. The negative
control (SRD-12B cells) was calculated with reference to the positive control (CHO-K1 Tet-On cells). Quantified GP-2 values are means6standard
deviations of three independent experiments. Asterisks indicate differences that are statistically significant (**, p,0.002; ***, p,0.0001).
doi:10.1371/journal.pntd.0000446.g003
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infected with (A) VSVDG/LASVGP or (B) VSVwt at an MOI of 0.2 in the presence (+) or absence (2) of doxycycline (Dox, 1 mg/ml). At 24 h post-
infection, virions in cell culture supernatants were pelleted through a 20% sucrose cushion by ultracentrifugation. Cell lysates and purified virions
were subjected to SDS-PAGE followed by immunoblotting using antisera specific for LASV GP and VSV proteins, respectively. Intracellular a1-AT
expression was analyzed using an anti-flag antibody. b-tubulin was used as a loading control.
doi:10.1371/journal.pntd.0000446.g004
Figure 5. Virus spread in a1-antitrypsin expressing cells. A. CHO-K1 Tet-On cells, SRD-12B cells and S1P-adapted a1-antitrypsin expressing
CHO cell lines were infected with VSVDG/LASVGP at an MOI of 0.02 in the presence (+) or absence (2) of doxycycline (Dox, 1 mg/ml). Infected cells
were immunostained 24 h post-infection using an antiserum against VSV and HRP-linked secondary antibody. Individual cells and virus spread were
visualized by subsequent application of True Blue peroxidase substrate. B. CHO-K1 Tet-On cells, S1P-adapted a1-antitrypsin variant RRIL cell line, as
well as the furin-specific a1-antitrypsin variant RVKR cell line, were infected with Fowl Plague virus (FPV) at an MOI of 0.001 in the presence (+)o r
absence (2) of doxycycline. At 24 h post-infection, immunostaining was performed as described above using a polyclonal FPV antiserum.
doi:10.1371/journal.pntd.0000446.g005
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reduced in cells expressing the S1P-specific a1-AT variant. At 24 h
post-infection virus production decreased about 100 fold in cells
expressing the a1-AT variant RRIL compared to non-induced
control cultures. The presence of a1-AT variant RRLL reduced
the virus titer in the supernatant about 10 fold, followed by a 6.2
fold reduction of virus production in a1-AT variant RRVL
expressing cells. The presence of the a1-AT variant RRYL only
exhibited a very moderate inhibitory effect on viral replication
(inhibition ,2 fold). Again, the presence of the furin-adapted a1-
AT variant RVKR did not affect VSVDG/LASVGP replication
compared to non-induced control cells. Our results indicate that
the various S1P-adapted a1-antitrypsins exhibit different inhibitory
potentials, due to their different recognition motifs. However, the
degree of inhibition of virus replication correlated well with the
inhibitory potential of the various S1P-adapted a1-antitrypsin
variants to block LASV GP processing. Interestingly, following the
inhibition of virus progeny over a time period of 48 h only the
S1P-adapted a1-AT variants RRIL and RRLL sustained their
inhibitory capacity, whereas in cells expressing a1-antitrypsin
variants RRVL and RRYL virus production was found to recover
although the initial expression levels of a1-antitrypsin variants
were similar (Table 1). These data indicate that the inhibitory
potential of the a1-AT variants RRVL and RRYL is not sufficient
to efficiently suppress the formation of infectious particles by
effectively blocking LASV GP-C cleavage, whereas the a1-AT
variants RRIL and RRLL seem to be appropriate candidates for
efficient inhibition of LASV propagation.
Inhibition of S1P impairs efficient LASV replication
Finally, we wanted to investigate the impact of blocking S1P-
mediated GP processing on virus progeny of authentic LASV.
Therefore, we assessed the inhibitory potential of the most potent
variant, a1-AT RRIL, on the multiplication of LASV (strain
Josiah). For this purpose a1-AT RRIL cells and, as controls, CHO-
K1-Tet-On and SRD-12B cells were infected with LASV at an
MOI of 0.1. To induce a1-AT expression, a1-AT RRIL cells and,
as a control for off-target effects, CHO-K1 Tet-On cells were
cultivated in the presence of doxycycline. To determine virus
titers, infectious virions released into the cell culture supernatant
were analyzed by defining the 50% tissue culture infectious dose
(TCID50) at various times post-infection, as indicated. In non-
induced a1-AT RRIL cells, LASV revealed a growth kinetic
similar to that observed in CHO-K1 Tet-On control cultures,
while expression of a1-AT RRIL resulted in an average 2 log10
reduction in viral titer (Fig. 6). The difference between infectious
LASV titers in the supernatant of a1-AT RRIL expressing cells
and SRD-12B cells correlated with the limited virus spread
observed in a1-AT RRIL expressing cells compared to single cell
infections in S1P null cells (Fig. 5). Taken together, this result
highlights the inhibitory activity of modified a1-antitrypsins against
LASV and demonstrates that inhibition of endogenous S1P is a
potent strategy to reduce the production of infectious LASV
progeny.
Discussion
Current drug treatment of Lassa fever and certain New World
hemorrhagic fevers is limited to the guanosine analogue ribavirin
[7,8,9]. Although ribavirin therapy can reduce the mortality rates
of severe clinical cases, its unavailability to most patients in West
Africa and South America as well as its association with severe
adverse effects including anaemia [11,13], teratogenicity and
embryo lethality [12], argues for the development of new
alternative treatment options.
In principle, every step in the viral life cycle is a potential target
for antiviral inhibitors. While current antiviral strategies in the
arenavirus field mainly target virus entry [58,59,60,61] or
replication and assembly [62,63,64,65,66,67], inhibition studies
of the glycoprotein activating endoprotease and its impact on viral
replication are largely unexploited. Due to its central role in the
arenavirus life cycle [23,26,33,34], S1P should be considered as a
cellular target for antiviral drug development. In the present study
we analyzed the inhibitory effect of S1P-adapted a1-antitrypsins
on proteolytic processing of LASV GP-C and its consequences for
viral replication. To our knowledge, this is the first report that
Table 1. Effect of a1-antitrypsin variants on VSVDG/LASVGP replication.
CHO-K1 Tet-On a1-AT variants Doxa time post-infection
24 h 48 h
virus titer [PFU/ml]
b fold decrease

































aCHO-K1 Tet-On AT cell lines were incubated in the absence (2) or presence (+) of doxycycline (Dox, 1 mg/ml) to induce expression of antitrypsin variants.
bCells were infected with VSVDG/LASVGP at a multiplicity of infection (MOI) of 0.02. Supernatants were collected 24 h and 48 h post-infection, respectively, and virus
titers were determined by plaque assay. Values shown are mean6standard deviation from 5 independent experiments.
cFold decrease of viral titers from Dox-induced cells compared to non-induced cells. An average from five independent experiments is shown, and asterisks indicate
statistically significant differences (*, p,0.05; **, p,0.002).
doi:10.1371/journal.pntd.0000446.t001
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GP-C cleavage and multicycle replication. Furin-adapted a1-ATs
have been shown to efficiently inhibit the formation of infectious
progeny of other viruses (e.g. HIV, measles virus and human
cytomegalovirus) [38,39,40,41,68,69].
Using a replication-competent recombinant VSV pseudotyped
with the LASV glycoprotein GP [48], we demonstrate that
proteolytic maturation of the precursor GP-C is sensitive to S1P-
adapted a1-ATs. Mutagenesis of the reactive centre loop (RCL)
into the S1P recognition motif RRIL resulted in an abrogation of
GP-C processing similar to that observed in S1P-deficient SRD-
12B cells. The inhibitory activity of the a1-AT variant RRIL on
LASV GP cleavage described here is in agreement with a previous
study showing its inhibitory potential on the processing of the
natural S1P substrates SREBP-2 and ATF6 [42]. Also an a1-AT
variant that contains the LASV GP-C cleavage motif RRLL
exhibited a high S1P inhibitory potential and was found to
drastically reduce GP processing. Interestingly, this variant
exhibited a 100% inhibition activity on maturation cleavage of
an artificial pro-PDGF (precursor of platelet-derived growth
factor) mutant that is processed by S1P due to introduction of a
RRLL cleavage site, but failed to inhibit cleavage of endogenously
expressed SREBP-2 [42]. These data indicate that various
substrates differ in their sensitivity towards S1P inhibition.
The outcome of severe illness increased significantly with the
level of viremia in Lassa fever patients [70]. Therefore, the extent
of multicycle replication of LASV and thus, the load of infectious
particles in its host organism have an important impact for the
progress of disease. Our studies revealed that a1-AT variants
RRIL and RRLL have a potency sufficient to sustain their
inhibitory capacity during multicycle replication, which resulted in
a significant reduction of virus infectivity. Inhibition of viral
replication correlated with the ability of the a1-AT variants RRIL
and RRLL to efficiently inhibit the processing of the LASV
glycoprotein precursor. Although our data demonstrated that
inhibition of glycoprotein cleavage by a1-AT RRIL reduced
incorporation of the subunits GP-1 and GP-2 into virions to below
detectable levels, the viral titer from a1-AT RRIL expressing cells
was found to be greater than that obtained from S1P null cells.
Based on this observation, we consider that even the most potent
a1-AT variant RRIL failed to entirely inhibit S1P activity.
However, given that S1P has important biological functions in
the regulation of various cellular processes, a complete inhibition
of the catalytic activity of S1P is not desirable. For a1-AT variants
RRVL and RRYL, we observed similar inhibition values by
immunoblot quantification analysis as described for CCHFV GP
cleavage [42]. Though, their inhibitory activity on LASV GP-C
cleavage was not sufficient to efficiently reduce virus replication of
VSVDG/LASVGP. These results should be taken into consider-
ation for experimental setups in future studies that address the
impact of S1P inhibition in arenavirus replication.
The most potent a1-AT variant RRIL revealed a similar
inhibitory potential on virus release of authentic LASV to that
observed with the corresponding VSVDG/LASVGP pseudotype.
Therefore, this study also demonstrates that the replication-
competent VSV expressing the LASV glycoprotein is an excellent
surrogate model for analyzing potential antivirals that target the
biological function of GP and its consequence for virus replication.
These studies can be performed under biosafety level 2 laboratory
conditions that would otherwise require biosafety level 4
laboratory conditions [71]. Taken together, our data indicate that
S1P-adapted a1-antitrypsins may represent a promising lead
compound for the development of a new class of anti-arenavirus
inhibitors.
In recent years improvements were made in the application of
bioengineered serpins to combat bacterial and viral infections
[39,72]. For example, the addition of exogenous a1-AT-PDX, a
potent and selective furin inhibitor, was found to efficiently block
human cytomegalovirus infection [39]. However, in contrast to
furin, which is known to recycle between the plasma membrane
and the TGN via endosomal compartments, membrane-bound
S1P is localized in the secretory pathway and can be sorted to
endosomal compartments but not to the cell surface [73,74,75].
Follow-up studies with small synthetic peptides, which are derived
from S1P-specific a1-antitrypsins described in the present work,
are currently in progress and will address cellular delivery and
organelle specific targeting, as well as their inhibitory potential on
authentic LASV replication. In analogy to inhibition strategies of
the eukaryotic subtilase furin, we previously designed and
developed a cell-permeable peptidyl chloromethylketone S1P
inhibitor, which contained the LASV GP-C cleavage site,
designated dec-RRLL-cmk [76,77,78]. This irreversible inhibitor
efficiently blocked the processing of LASV GP at nanomolar
concentrations, however, because of cell type-dependent toxicity
observed by us and others, its potential in vitro use requires further
investigation [79,80].
Due to the essential roles of S1P in cholesterol metabolism and
fatty acid synthesis, this enzyme has attracted great attention by
the pharmaceutical industry. Research efforts are currently
directed towards the development of S1P inhibitors that may be
used in the treatment of dyslipidemia and a variety of
cardiometabolic risk factors associated with diabetes and obesity
[81]. Identification of specific S1P inhibitors in this therapeutic
area may also be beneficial in treatment of hemorrhagic fevers
caused by viruses known to be processed by S1P. Future studies
Figure 6. Impact of S1P-adapted a1-AT variant RRIL on LASV
replication. CHO-K1 Tet-On, SRD-12B and a1-AT variant RRIL CHO cell
lines were infected with LASV (strain Josiah) at an MOI of 0.1 in the
presence (+) or absence (2) of doxycycline (Dox, 1 mg/ml). At various
times post-infection as indicated, cell culture supernatants were
collected and virus yields were determined by TCID50. Values shown
are mean results6standard deviation of three independent experi-
ments performed in duplicate. Asterisks indicate differences that are
statistically significant between induced a1-AT variant RRIL cells in
comparison to non-induced cells (*, p,0.05).
doi:10.1371/journal.pntd.0000446.g006
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novel S1P inhibitors that have been developed [82,83].
While most conventional antiviral drugs target proteins that are
virus-encoded, cellular proteins essential for viral replication are
currently considered to be alternative potential targets for antiviral
therapy [84,85,86]. With the exception of Ebola virus, whose
glycoprotein cleavage by the proprotein convertase furin is not
essential for virus replication in cell culture and virulence in
nonhuman primates [71,87,88,89], maturation cleavage of surface
glycoproteins of several virus species by endoproteases is a key
determinant for host cell tropism and pathogenicity [90]. Thus,
the emergence of viral escape mutants that confer resistance due to
targeted inhibition of an endogenous protease is rather unlikely. In
S1P-deficient SRD-12B cells, which were persistently infected with
Junin virus vaccine strain Candid 1, no virus escape variants
possessing a cleavage motif other than a S1P recognition motif
have evolved, indicating a low potential of arenaviruses to develop
de novo a different glycoprotein maturation pathway [33]. This
observation together with our findings that inhibition of S1P
significantly affects LASV GP processing and virus infectivity
should encourage the development of S1P inhibitors as a potential
drug target to counteract infections caused by pathogenic
arenaviruses.
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